

Certificate of Analysis

PIK3C3 (hVPS34), 20 µg

Phosphoinositide-3-Kinase, Class 3, GST-tagged



Part Number: PV5126
Lot Number: 853378D
Immediate Storage: -80°C
Shipping Conditions: dry ice

5791 Van Allen Way
Carlsbad, CA 92008
Phone: 760.603.7200
Fax: 760.602.6500
www.lifetechnologies.com

Description:

Recombinant human full-length protein, GST-tagged, expressed in insect cells. No special measures were taken to activate this kinase.

Specific Activity:

23 nmoles of ADP formed per minute per mg of total protein using the Adapta® Assay (PV5099). An ADP/ATP standard curve is used to calculate percent conversion of ATP to ADP. PIK3C3 (hVPS34) activity determined at a final protein concentration of 156 ng/mL.

Concentration:

0.94 mg/mL total protein as measured using the Bradford protein assay with BSA as a standard.

Calculated **7,290 nM**.

Aliases:

Vps34, hVps34, hsVps34, MGC61518

Storage and Handling:

For maximum recovery please spin prior to use. Aliquots of the 5 µg, 10 µg and 20 µg sizes of kinase are not recommended as materials can be used in original packaging until exhausted. For larger sizes, the number of freeze/thaws may be reduced by preparing aliquots, aliquots below 20 µL are not recommended. **Please never store a kinase diluted.** If properly stored at -80°C, this product is guaranteed for 6 months from date of purchase.

Storage Buffer:


50 mM Tris (pH 7.5), 150 mM NaCl, 0.5 mM EDTA, 0.02% CHAPS, 2 mM DTT and 50% Glycerol.

Assay Buffer:

50 mM HEPES (pH 7.5), 2 mM MnCl₂, 0.1% CHAPS, 1 mM EGTA and 2 mM DTT prepared from 5X Kinase Buffer Q (PV5125) with MnCl₂ and DTT added.

QUALITY ASSURANCE

PIK3C3 (hVPS34) Activity Graph



Assay Conditions:

PIK3C3 (hVPS34) was diluted in assay buffer and the activity determined in a 10 µL Adapta® Assay (PV5099) with 10 µM ATP and 100 µM PI:PS Lipid Kinase Substrate (PV5122) at room temperature for 1 hour. The reaction was stopped with a 5 µL addition of EDTA and detection reagents. The final concentrations are 10 mM EDTA, 2 nM Adapta® Eu-anti-ADP Antibody and 10 nM Alexa Fluor® 647 ADP Tracer. The plate was read after a 45 minute room temperature incubation.

Gel Information for PIK3C3 (hVPS34)

Page Description: The SDS-PAGE and/or Native PAGE were run on 4-20% Tris-Glycine Novex® gels (Catalog #: EC6025BOX).


Lane 1: Invitrogen™ BenchMark™ Protein Ladder (Catalog #: 10747-012).

Lane 2: 1 µg PIK3C3 (hVPS34)

Lane 3: 2 µg PIK3C3 (hVPS34)

Lane 4: 5 µg PIK3C3 (hVPS34)

Lane 5: 10 µg PIK3C3 (hVPS34)



Purity:

95% as determined by a Coomassie® blue stained SDS-PAGE gel.

Molecular Weight:

129.0 kDa calculated from the protein sequence(s). Calculated from the protein sequence(s).

Mass Spectrometry:

PIK3C3 (hVPS34) was subjected to proteolytic digest followed by mass spec analysis. The resulting MS/MS data verified PIK3C3 (hVPS34) identity by comparison against the amino acid sequence(s) of the recombinant protein.

Protein sequence alignment with reference sequence(s)

GenBank Accession Number: NP_002638.2

1	MAPILGYWKI	KGLVQPTRLL	LEYLEEKYE	HLYERDEGDK	WRNKKFELGL	EFNPYPYID	GDVKLTQSM	IIRYIADKHN	MLGGCPKERA	EISMLEGAVL	GST TAG
1	MAPILGYWKI	KGLVQPTRLL	LEYLEEKYE	HLYERDEGDK	WRNKKFELGL	EFNPYPYID	GDVKLTQSM	IIRYIADKHN	MLGGCPKERA	EISMLEGAVL	IVGN PIK3C3
1	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	NP_002638.2
101	DIRYGVSRIA	YSKDFETLV	DFLSKLPEML	KMFEDRLCHK	TYLNGDHVTH	PDFMLYDALD	VVLYMDPMCL	DAFPKLVCFK	KRIEAIQID	KYLKSSKYIA	
101	DIRYGVSRIA	YSKDFETLV	DFLSKLPEML	KMFEDRLCHK	TYLNGDHVTH	PDFMLYDALD	VVLYMDPMCL	DAFPKLVCFK	KRIEAIQID	KYLKSSKYIA	
1	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	
201	WPLQGWQATF	GGGDHPPKSD	LVPR								
201	WPLQGWQATF	GGGDHPPKSD	LVPRHNTQSL	YKKAGTMGEA	EKFHYIYSCD	LDINVQLKIG	SLEGKREQKS	YKAVLEDPML	KFSGLYQETC	SDLYVTQCQV	
1	-----	-----	-----	-----MGEA	-----EKFHYIYSCD	-----LDINVQLKIG	-----SLEGKREQKS	-----YKAVLEDPML	-----KFSGLYQETC	-----SDLYVTQCQV	
224											
301	AEGKPLALPV	RTSYKAFSTR	WNWNEWLKL	VKYPDLPRNA	QVALTIWDVY	GPVKAVPVGG	TTVSLFGKYG	MFRQGMHDLK	VWPNVEADGS	EPTKTPGRTS	
65	AEGKPLALPV	RTSYKAFSTR	WNWNEWLKL	VKYPDLPRNA	QVALTIWDVY	GPVKAVPVGG	TTVSLFGKYG	MFRQGMHDLK	VWPNVEADGS	EPTKTPGRTS	
224											
401	STLSEDMQSR	LAKLTKAHRQ	GHHVKVDWLD	RLTFREIEMI	NESEKRSSNF	MYLMVEFRCV	KCDDKEYGIV	YYEKDGDSS	PILTSFELVK	VPDPQMSMEN	
165	STLSEDMQSR	LAKLTKAHRQ	GHHVKVDWLD	RLTFREIEMI	NESEKRSSNF	MYLMVEFRCV	KCDDKEYGIV	YYEKDGDSS	PILTSFELVK	VPDPQMSMEN	
224											
501	LVESKHHKLA	RSLSRSGSDH	DLKPNAATRD	QLNIIVSYPP	TKQLTYEEQD	LVMKFRYYLT	NQEKALTKFL	KCVNWDLPQE	AKQALELLGK	WKPMDDVEDSL	
265	LVESKHHKLA	RSLSRSGSDH	DLKPNAATRD	QLNIIVSYPP	TKQLTYEEQD	LVMKFRYYLT	NQEKALTKFL	KCVNWDLPQE	AKQALELLGK	WKPMDDVEDSL	
224											
601	ELLSSHYTNP	TVRRYAVARL	ROADDEDLLM	YLLQLVQALK	YENFDDIKNG	LEPTKKDSQS	SVSENVNSNG	INSAEIDSSQ	IITSPLPSVS	SPPPAASKTKE	
365	ELLSSHYTNP	TVRRYAVARL	ROADDEDLLM	YLLQLVQALK	YENFDDIKNG	LEPTKKDSQS	SVSENVNSNG	INSAEIDSSQ	IITSPLPSVS	SPPPAASKTKE	
224											
701	VPDGENLEQD	LCTFLISRAC	KNSTLANLYL	WYVIVECEDQ	DTQQRDPKTH	EMYNVMRRF	SQALLKGDKS	VRVMRSLAA	QOTFVDRLVH	LMKAVQRESG	
465	VPDGENLEQD	LCTFLISRAC	KNSTLANLYL	WYVIVECEDQ	DTQQRDPKTH	EMYNVMRRF	SQALLKGDKS	VRVMRSLAA	QOTFVDRLVH	LMKAVQRESG	
224											
801	NRKKKNERLQ	ALLGDNEKMN	LSDELIVPL	LEPQVKIRGI	IPETATLFKS	ALMPAQLFFK	TEDGGKYPVI	FKHGDDLQD	QLILQIISLM	DKLLRKENLD	
565	NRKKKNERLQ	ALLGDNEKMN	LSDELIVPL	LEPQVKIRGI	IPETATLFKS	ALMPAQLFFK	TEDGGKYPVI	FKHGDDLQD	QLILQIISLM	DKLLRKENLD	
224											
901	LKLTPTYKVL	TSTKHGFMQF	IQSVPVAEVL	DTEGSIQNFF	RKYAPSENGP	NGISAEVMDT	YVKSCAGYCV	ITYILGVGDR	HLNLLLTKT	GKLFHIDFGY	
665	LKLTPTYKVL	TSTKHGFMQF	IQSVPVAEVL	DTEGSIQNFF	RKYAPSENGP	NGISAEVMDT	YVKSCAGYCV	ITYILGVGDR	HLNLLLTKT	GKLFHIDFGY	
224											
1001	ILGRDPKPLP	PPMKLNKEMV	EGMGGTQSEQ	YQEFRKQCYT	AFLHLRRYSN	LILNLFSLMV	DANIPDIALE	PDKTVKKVQD	KFRDLSDDEE	AVHYMQSLID	
765	ILGRDPKPLP	PPMKLNKEMV	EGMGGTQSEQ	YQEFRKQCYT	AFLHLRRYSN	LILNLFSLMV	DANIPDIALE	PDKTVKKVQD	KFRDLSDDEE	AVHYMQSLID	
224											
1101	ESVHALFAAV	VEQIHKFAQY	WRK								
865	ESVHALFAAV	VEQIHKFAQY	WRK								

* highlighted residues denote differences from the reference protein sequence(s).

Becky Baker

Becky. Baker, QA Engineer II

Date: 11/Apr/2012

Adapta® is a registered trademark of Life Technologies Corporation.
Novex® s a registered trademark of Life Technologies Corporation.
Invitrogen™ is a trademark of Life Technologies Corporation.
BenchMark™ is a trademark of Life Technologies Corporation.
Coomassie® is a registered trademark of Imperial Chemical Industries.

Limited Use Label License: Research Use Only

These products may be covered by one or more Limited Use Label Licenses (see Invitrogen catalog or www.invitrogen.com). By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. O-091089 0110

All rights reserved. The trademarks mentioned herein are the property of Life Technologies Corporation or their respective owners.

For research use only. Not intended for human or animal therapeutic or diagnostic use.